

Francesco Saverio Di Leva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3493743/publications.pdf>

Version: 2024-02-01

51
papers

1,679
citations

218381

26
h-index

301761

39
g-index

51
all docs

51
docs citations

51
times ranked

2778
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2716-2746.	2.9	149
2	The organometallic ferrocene exhibits amplified anti-tumor activity by targeted delivery via highly selective ligands to $\alpha_3\beta_1$, $\alpha_6\beta_1$, or $\alpha_5\beta_1$ integrins. <i>Biomaterials</i> , 2021, 271, 120754.	5.7	14
3	Halting the Spread of Herpes Simplex Virus-1: The Discovery of an Effective Dual $\alpha_6\beta_1/\alpha_8\beta_1$ Integrin Ligand. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6972-6984.	2.9	9
4	Discovery of dihydroxyindole-2-carboxylic acid derivatives as dual allosteric HIV-1 Integrase and Reverse Transcriptase associated Ribonuclease H inhibitors. <i>Antiviral Research</i> , 2020, 174, 104671.	1.9	14
5	Click Chemistry (CuAAC) Trimerization of an $\alpha_6\beta_1$ Integrin Targeting Ga ⁶⁸ Peptide: Enhanced Contrast for in vivo PET Imaging of Human Lung Adenocarcinoma Xenografts. <i>ChemBioChem</i> , 2020, 21, 2836-2843.	1.3	20
6	GPBAR1 Activation by C6-Substituted Hyodeoxycholate Analogues Protect against Colitis. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 818-824.	1.3	8
7	Disulfide Bond Replacement with 1,4- and 1,5-Disubstituted [1,2,3]-Triazole on CX ₄ Chemokine Receptor Type 4 (CXCR4) Peptide Ligands: Small Changes that Make Big Differences. <i>Chemistry - A European Journal</i> , 2020, 26, 10113-10125.	1.7	10
8	Bioinformatics and Biosimulations as Toolbox for Peptides and Peptidomimetics Design: Where Are We?. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 66.	1.6	34
9	Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 149, 105337.	1.9	15
10	Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators. <i>Handbook of Experimental Pharmacology</i> , 2019, 256, 111-136.	0.9	8
11	Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties. <i>Molecules</i> , 2019, 24, 1043.	1.7	3
12	Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1. <i>Scientific Reports</i> , 2019, 9, 2504.	1.6	13
13	Selective Targeting of Integrin $\alpha_8\beta_1$ by a Highly Active Cyclic Peptide. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2024-2037.	2.9	33
14	Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 504-510.	1.3	27
15	Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 407-412.	1.3	27
16	Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4) Ligand Interactions on Living Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2910-2923.	2.9	22
17	<i>N</i> -Methylation of <i>iso</i> DGR Peptides: Discovery of a Selective $\alpha_5\beta_1$ -Integrin Ligand as a Potent Tumor Imaging Agent. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2490-2499.	2.9	18
18	From a Helix to a Small Cycle: Metadynamics-Inspired $\alpha_6\beta_1$ Integrin Selective Ligands. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 14645-14649.	7.2	26

#	ARTICLE	IF	CITATIONS
19	Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4791-4809.	2.9	22
20	Von einer Helix zu einem kleinen Ring: Metadynamik-inspirierte, selektive Liganden für Integrin. <i>Angewandte Chemie</i> , 2018, 130, 14856-14860.	1.6	3
21	Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists. <i>Scientific Reports</i> , 2017, 7, 43290.	1.6	30
22	Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3626-3635.	2.9	24
23	Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin α . <i>Angewandte Chemie - International Edition</i> , 2017, 56, 16405-16409.	7.2	30
24	Lösung des Problems mangelnder oraler Verfügbarkeit cyclischer Hexapeptide: Entwicklung eines selektiven, oral verfügbaren Liganden für das Integrin α . <i>Angewandte Chemie</i> , 2017, 129, 16624-16629.	1.6	5
25	Epoxide functionalization on cholane side chains in the identification of G-protein coupled bile acid receptor (GPBAR1) selective agonists. <i>RSC Advances</i> , 2017, 7, 32877-32885.	1.7	4
26	Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9641-9652.	2.9	21
27	Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases. <i>Frontiers in Pharmacology</i> , 2017, 8, 162.	1.6	23
28	Stabile Peptide statt "gestapelte Peptide": hochaffine selektive Integrinliganden. <i>Angewandte Chemie</i> , 2016, 128, 1559-1563.	1.6	11
29	Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8369-8380.	2.9	26
30	New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H. <i>Antiviral Research</i> , 2016, 134, 236-243.	1.9	35
31	Stable Peptides Instead of Stapled Peptides: Highly Potent Selective Integrin Ligands. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 1535-1539.	7.2	59
32	Monothiocarbamates Strongly Inhibit Carbonic Anhydrases In Vitro and Possess Intraocular Pressure Lowering Activity in an Animal Model of Glaucoma. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5857-5867.	2.9	54
33	The ring residue proline 8 is crucial for the thermal stability of the lasso peptide caulosegnin II. <i>Molecular BioSystems</i> , 2016, 12, 1106-1109.	2.9	35
34	Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism. <i>Scientific Reports</i> , 2015, 5, 16605.	1.6	23
35	Discovery of N-aryl-naphthylamines as in vitro inhibitors of the interaction between HIV integrase and the cofactor LEDGF/p75. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 288-294.	2.6	16
36	N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4610-4623.	2.9	38

#	ARTICLE	IF	CITATIONS
37	Identification of Highly Conserved Residues Involved in Inhibition of HIV-1 RNase H Function by Diketo Acid Derivatives. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6101-6110.	1.4	64
38	Mechanistic insight into ligand binding to G-quadruplex DNA. <i>Nucleic Acids Research</i> , 2014, 42, 5447-5455.	6.5	79
39	Basic Quinolinonyl Diketo Acid Derivatives as Inhibitors of HIV Integrase and their Activity against RNase H Function of Reverse Transcriptase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3223-3234.	2.9	51
40	Modification on Ursodeoxycholic Acid (UDCA) Scaffold. Discovery of Bile Acid Derivatives As Selective Agonists of Cell-Surface G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7687-7701.	2.9	62
41	Pharmacophoric Modifications Lead to Superpotent $\alpha_5\beta_3$ Integrin Ligands with Suppressed $\alpha_5\beta_1$ Activity. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3410-3417.	2.9	35
42	Design, Synthesis, and Biological Evaluation of Potent Dual Agonists of Nuclear and Membrane Bile Acid Receptors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 937-954.	2.9	79
43	Rational Improvement of the Affinity and Selectivity of Integrin Binding of Grafted Lasso Peptides. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5829-5834.	2.9	68
44	Marine and Semi-Synthetic Hydroxysteroids as New Scaffolds for Pregnane X Receptor Modulation. <i>Marine Drugs</i> , 2014, 12, 3091-3115.	2.2	13
45	Phenylpyrazolo[1,5- <i>a</i>]quinazolin-5(4 <i>H</i>)-one: A Suitable Scaffold for the Development of Noncamptothecin Topoisomerase I (Top1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7458-7462.	2.9	43
46	Binding Mechanism of the Farnesoid X Receptor Marine Antagonist Suvanine Reveals a Strategy To Forestall Drug Modulation on Nuclear Receptors. Design, Synthesis, and Biological Evaluation of Novel Ligands. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4701-4717.	2.9	49
47	Exploring the Chemical Space of G-Quadruplex Binders: Discovery of a Novel Chemotype Targeting the Human Telomeric Sequence. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9646-9654.	2.9	48
48	Biselectivity of isoDGR Peptides for Fibronectin Binding Integrin Subtypes $\alpha_5\beta_1$ and $\alpha_5\beta_6$: Conformational Control through Flanking Amino Acids. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1509-1519.	2.9	67
49	State-of-the-Art Methodologies for the Discovery and Characterization of DNA G-Quadruplex Binders. <i>Current Pharmaceutical Design</i> , 2012, 18, 1880-1899.	0.9	40
50	Protein Flexibility in Virtual Screening: The BACE-1 Case Study. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 2697-2704.	2.5	47
51	Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: A first round of lead optimization. <i>European Journal of Medicinal Chemistry</i> , 2012, 47, 143-152.	2.6	25